P01.141 Different timing to use bevacizumab in patients with recurrent glioblastoma: early versus delayed administration

BACKGROUND: Glioblastoma (GBM) is the most baleful malignant brain tumor in adults. After a diagnosis of relapsed GBM, multimodality salvage treatment are not incisive enough to improve overall survival (OS) beyond a few months, and their best use and the timing is not well established. Bevacizumab...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Gonnelli, A, Pasqualetti, F, Molinari, A, Cantarella, M, Montrone, S, Mattioni, R, Baldaccini, D, Fabrini, M, Paiar, F
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Poster Presentations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144527/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.183
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki